KR930701201A - Immunoreactive compounds - Google Patents

Immunoreactive compounds

Info

Publication number
KR930701201A
KR930701201A KR1019920703408A KR920703408A KR930701201A KR 930701201 A KR930701201 A KR 930701201A KR 1019920703408 A KR1019920703408 A KR 1019920703408A KR 920703408 A KR920703408 A KR 920703408A KR 930701201 A KR930701201 A KR 930701201A
Authority
KR
South Korea
Prior art keywords
compound according
immunoreactive
iga
igm
fragment
Prior art date
Application number
KR1019920703408A
Other languages
Korean (ko)
Inventor
에보 시브렌 보스
페트루스 요한네스 분
Original Assignee
에프.지.엠.헤르만스.에이.지.제이.베르미렌
악조 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프.지.엠.헤르만스.에이.지.제이.베르미렌, 악조 엔.브이. filed Critical 에프.지.엠.헤르만스.에이.지.제이.베르미렌
Publication of KR930701201A publication Critical patent/KR930701201A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

본 발명에 의하면, HSA, 효소 또는 면역원성이 낮은 합성 폴리펩티드와 같은 캐리어 분자에 커플링된 IgM 또는 IgA의 항원-결합 단편을 하나 이상 포함하는 신규의 면역반응성 화합물이 제공된다. 이들 단편을 캐리어에 커플링함으로써, 이들의 비교적 낮은 항원 친화력을 천연 IgM 또는 IgA의 친화력 수준에 버금가는 상당한 수준까지 복구된다.According to the present invention, novel immunoreactive compounds are provided comprising one or more antigen-binding fragments of IgM or IgA coupled to a carrier molecule, such as HSA, an enzyme or a low immunogenic synthetic polypeptide. By coupling these fragments to a carrier, their relatively low antigen affinity is restored to a significant level comparable to that of native IgM or IgA.

Description

면역반응성 화합물Immunoreactive compounds

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (12)

적오도 하나의 폴리펩티드에 커플링된 IgM 또는 IgA의 항원 결합 단편을 포함하는 면역반응성 화합물Immunoreactive compounds comprising an antigen binding fragment of IgM or IgA coupled to at least one polypeptide 제1항에 있어서, 상기 단편이 인체 IgM 또는 IgA의 것임을 특징으로 하는 면역반응성 화합물.2. The immunoreactive compound of claim 1, wherein the fragment is of human IgM or IgA. 제1 또는 2항에 있어서, 상기 IgM 또는 IgA는 종양-관련 항원에 대해 지향하는 것임을 특징으로 하는 면역반응성 화합물.The immunoreactive compound of claim 1 or 2, wherein the IgM or IgA is directed against a tumor-associated antigen. 제1 내지 3항중 어느 한항에 있어서, 상기 폴리펩티드가 인체 단백질인 것을 특징으로 하는 면역반응성 화합물.The immunoreactive compound according to any one of claims 1 to 3, wherein the polypeptide is a human protein. 제1 내지 4항중 어느 한 항에 있어서, 상기 폴리펩티드가 인체 혈청 알부민 또는 그의 단편인 것을 특징으로 하는 면역반응성 화합물.The immunoreactive compound according to any one of claims 1 to 4, wherein the polypeptide is human serum albumin or a fragment thereof. 제1 내지 4항중 어느 한 하에 있어서, 상기 폴리펩티드가 효소인 것을 특징으로 하는 면역반응성 화합물.The immunoreactive compound according to any one of claims 1 to 4, wherein the polypeptide is an enzyme. 제1 내지 6항중 어느 한 항에 있어서, 상기 폴리펩티드에 추가로 하나 이상의 표지체가 커플링되어 있는 것을 특징으로 하는 면역반응성 화합물.The immunoreactive compound according to any one of claims 1 to 6, wherein at least one label is further coupled to the polypeptide. 제1 내지 7항중 어느 한 항에 있어서, 상기 단편이 IgM 또는 IgA의 단령체인 것을 특징으로 하는 면역반응성 화합물.The immunoreactive compound according to any one of claims 1 to 7, wherein the fragment is an IgM or a monomer of IgA. 제1 내지 8항중 어느 한 항에 있어서, 상기 단편이 IgM 또는 IgA의 F(ad′)2단편인 것을 특징으로 하는 면역반응성 화합물.9. An immunoreactive compound according to any one of claims 1 to 8, wherein said fragment is an F (ad ') 2 fragment of IgM or IgA. 적어도 하나의 종양사멸성 화합물이 결합되어 있는 제1 내지 9항중 어느 한항에 따른 면역반응성 화합물을 함유하는 치료적 활성 조성물.A therapeutically active composition comprising an immunoreactive compound according to any one of claims 1 to 9 in which at least one oncolytic compound is bound. 적어도 하나의 진단용으로 유용한 그룹이 결합되어 있는 제1 내지 9항중 어느 한 항에 따른 면역반응성 화합물을 함유하는 발암 진단용 조성물.A composition for diagnosing carcinogenesis comprising an immunoreactive compound according to any one of claims 1 to 9 in which at least one group for diagnosis is combined. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019920703408A 1990-07-03 1991-06-28 Immunoreactive compounds KR930701201A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP90201781.3 1990-07-03
EP90201781 1990-07-03
PCT/EP1991/001223 WO1992000763A1 (en) 1990-07-03 1991-06-28 Immunoreactive compound

Publications (1)

Publication Number Publication Date
KR930701201A true KR930701201A (en) 1993-06-11

Family

ID=8205056

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920703408A KR930701201A (en) 1990-07-03 1991-06-28 Immunoreactive compounds

Country Status (7)

Country Link
EP (1) EP0537222A1 (en)
JP (1) JPH05507924A (en)
KR (1) KR930701201A (en)
CA (1) CA2086531A1 (en)
FI (1) FI925804A (en)
HU (1) HUT63343A (en)
WO (1) WO1992000763A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9824632D0 (en) * 1998-11-10 1999-01-06 Celltech Therapeutics Ltd Biological compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981002522A1 (en) * 1980-03-03 1981-09-17 M Goldenberg Tumor localization and therapy with labeled antibodies and antibody fragments specific to tumor-associated markers
CA1168150A (en) * 1981-12-18 1984-05-29 The Governors Of The University Of Alberta Targeting conjugates of albumin and therapeutic agents
NZ210867A (en) * 1984-01-31 1989-01-06 Litton Bionetics Inc Tumour-specific monoclonal antibodies, production thereof and use
EP0293524A1 (en) * 1987-06-02 1988-12-07 Vasocor Atherosclerotic plaque immunoassay
JPH01257263A (en) * 1987-06-19 1989-10-13 Agouron Inst:The Sm-d antigen, cloning thereof and detection of seeding erythematosus by use thereof
DE3875852T2 (en) * 1987-08-10 1993-03-18 Miles Inc CLEANED IGM.
US4937183A (en) * 1988-02-03 1990-06-26 Cytogen Corporation Method for the preparation of antibody-fragment conjugates
JPH03503117A (en) * 1988-02-12 1991-07-18 ハイテク　レセプター　アーベー Immunoglobulin-binding substances, their subfragments, their production methods, reagent kits, and immunoglobulin-binding substances
US4983529A (en) * 1988-06-10 1991-01-08 Abbott Laboratories Immunoassay for HIV-I antigens using F(AB')2 fragments as probe
KR900005995A (en) * 1988-10-31 1990-05-07 우메모또 요시마사 Modified Interleukin-2 and Method of Making the Same
WO1990011091A1 (en) * 1989-03-27 1990-10-04 Centocor, Inc. FORMULATIONS FOR STABILIZING OF IgM ANTIBODIES

Also Published As

Publication number Publication date
EP0537222A1 (en) 1993-04-21
WO1992000763A1 (en) 1992-01-23
CA2086531A1 (en) 1992-01-04
FI925804A0 (en) 1992-12-21
HUT63343A (en) 1993-08-30
HU9204170D0 (en) 1993-04-28
JPH05507924A (en) 1993-11-11
FI925804A (en) 1992-12-21

Similar Documents

Publication Publication Date Title
ATE128732T1 (en) ANTIGEN CONSTRUCTS OF ''MAJOR HISTOCOMPATIBILITY COMPLEX'' CLASS I ANTIGENS WITH SPECIFIC CARRIER MOLECULES, THEIR PRODUCTION AND USE.
DK0673255T3 (en) Monoclonal antibodies that specifically bind to vascular tumor endothelium and applications thereof
BR9810907A (en) Monoclonal and polyclonal antibodies, peptide capable of generating an antibody, immunogenic agent, nucleotide sequence, pharmaceutical composition, use of at least one antibody, diagnostic kit, and process for preparing an immunogenic agent
DE69807679T2 (en) COMPOSITIONS OF CONJUGATES OF THE STABLE, ACTIVE, HUMAN OB PROTEINS WITH THE FC CHAIN OF IMMUNOGLOBULINES AND RELATED PROCEDURES
EP0683234A4 (en) ANTIBODY AGAINST -g(b)-AMYLOID OR DERIVATIVE THEREOF AND USE THEREOF.
PT752876E (en) MONOCLONIC ANTIBODIES THAT CONNECT WITH THE ANTIGENE PATH OF MAGE-1, MAGE-1, MAGE-1 TUMOR REJECTION, AND MAGE-1 DERIVED IMMUNOGENIC PEPTIDES
DK0523395T3 (en) Seroreactive regions on proteins E1 and E2 in HPV 16
DE59309458D1 (en) Synthetic peptides, antibodies against them and their use
KR900013986A (en) Monoclonal Antibodies to Tumor-Related Antigens (MAb_s), Methods for Making and Uses thereof
Atassi et al. Localization and verification by synthesis of five antigenic sites of bovine serum albumin
EP0722499A4 (en) Immunoreactive antigens of hepatitis e virus
AU612683B2 (en) Synthetic peptides, antibodies directed against them, and the use thereof
KR930701201A (en) Immunoreactive compounds
ES2082132T3 (en) COMPOSITION CONTAINING AT LEAST TWO DIFFERENT ANTIBODIES OR FRAGMENTS OF THEM.
CA2067584A1 (en) Agglutinant complex as blood typing reagent
Carding et al. Multiple proteins related to the soluble galactose-binding animal lectin revealed by a monoclonal anti-lectin antibody
ATE345501T1 (en) ELISA SERODIAGNOSIS OF SWINE PLEUROPNEUMONIA SEROTYPE 2
GB2299994A (en) Equine arteritis virus peptides antibodies and their use in a diagnostic test
Stepanik et al. Primary structure of human alpha 2-macroglobulin. III. Primary structure of three large disulfide-bridged CNBr fragments, located in the COOH-terminal part of alpha 2-macroglobulin and accounting for 301 residues.
Sanderson et al. Interchange of Allospecific MHC Class 1 Peptide Chains with Xenospecific β2Microglobulin and its Implications for Genetic Restriction
KR890010191A (en) Vaccines against Manson Blood Insects
GB2333295A (en) Modified protein G and fragments thereof

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid